Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.
about
Botulinum toxin A for the Treatment of Overactive BladderOveractive bladderThe efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladderOnabotulinumtoxinA for the treatment of overactive bladderFactors associated with dose escalation of fesoterodine for treatment of overactive bladder in people >65 years of age: A post hoc analysis of data from the SOFIA study.Real life persistence rate with antimuscarinic treatment in patients with idiopathic or neurogenic overactive bladder: a prospective cohort study with solifenacin.Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy.Randomized controlled trial of cyclic and continuous therapy with trospium and solifenacin combination for severe overactive bladder in elderly patients with regard to patient complianceMedication adherence in the management of nocturia: challenges and solutions.Denervation suppresses gastric tumorigenesis.Effect of pharmacological treatment for urinary incontinence in the elderly and frail elderly: A systematic review.The investigation and treatment of female pelvic floor dysfunction.Persistence and adherence with the new beta-3 receptor agonist, mirabegron, versus antimuscarinics in overactive bladder: Early experience in CanadaAdherence and persistence of mirabegron and anticholinergic therapies in patients with overactive bladder: a real-world claims data analysis.Subject-Controlled, On-demand, Dorsal Genital Nerve Stimulation to Treat Urgency Urinary Incontinence; a Pilot.Translation and Linguistic Validation of the Korean Version of the "Benefit, Satisfaction, and Willingness to Continue" Questionnaire for Patients With Overactive Bladder.Anticholinergics for overactive bladder: Temporal trends in prescription and treatment persistence.Evaluating Outcomes in Patients with Overactive Bladder within an Integrated Healthcare Delivery System Using a Treatment Patterns AnalyzerTreatment compliance of working persons to high-dose antimuscarinic therapies: a randomized trialThe attitudes of Urologists and Gynecologists about overactive bladder and treatment of it in Turkey: A questionnaire survey.Long-term adherence to antimuscarinic drugs when treating overactive bladder in the older: Subjective reason and objective factors.An update on the pharmacotherapy for lower urinary tract dysfunction.Urinary considerations for adult patients with spinal dysraphism.Overactive Bladder and the β3-Adrenoceptor Agonists: Current Strategy and Future Prospects.Patient-perceived effectiveness and impact on quality of life of solifenacin in combination with an α-blocker in men with overactive bladder in Sweden: a non-interventional study.Safety, Efficacy, and Persistence of Long-Term Mirabegron Treatment for Overactive Bladder in the Daily Clinical Setting: Interim (1-Year) Report from a Japanese Post-Marketing Surveillance Study.The effectiveness of transcutaneous tibial nerve stimulation (TTNS) for adults with overactive bladder syndrome: A systematic review.Safety and tolerability of β3-adrenoceptor agonists in the treatment of overactive bladder syndrome - insight from transcriptosome and experimental studies.Can we create a valid treatment algorithm for patients with drug resistant overactive bladder (OAB) syndrome or detrusor overactivity (DO)? Results from a think tank (ICI-RS 2015).Real-life clinical practice of onabotulinum toxin A intravesical injections for overactive bladder wet: an Italian consensus statement.Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias.Persistence with medication and overactive bladder: an ongoing challenge.Clinical and economic impact of mirabegron compared with antimuscarinics for the treatment of overactive bladder in Canada.Effectiveness of motivational interviewing interventions on medication adherence in adults with chronic diseases: a systematic review and meta-analysis.Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia.Limitations of anticholinergic cycling in patients with overactive bladder (OAB) with urinary incontinence (UI): results from the CONsequences of Treatment Refractory Overactive bLadder (CONTROL) study.Tolerability and persistence in a large, prospective case series of women prescribed mirabegron.Persistence with mirabegron therapy for overactive bladder: A real life experience.Interventions do not enhance medication persistence and compliance in patients with overactive bladder: a 24 weeks, randomised, open-label, multi-center trial.
P2860
Q26764765-1FE1AD37-1D6D-4704-A170-110F9F0ED1B5Q26766174-5AEFDFAA-894B-4B47-81E0-E442053CA7C8Q26770419-EBAEB6A4-D717-4061-9003-1F70C6010D4FQ27002371-EED318AF-DE7A-4674-A39C-3B82079A2239Q30794849-1EF8BFFA-4A55-4094-9014-24534DCECB7FQ33560320-6990F507-248E-4CEB-BDEF-56794EDD0FC2Q33696642-613A4251-9570-483E-B5F1-A0689B82B33DQ33863110-3F6EE7B5-3C2F-482A-B651-92AD57405064Q34536721-A833F8E7-4928-41DE-8504-EF4CB6D7452FQ34982181-FD0AF432-E588-4A32-812A-8E8D88DB9474Q35219277-F5EFA28E-A865-45F4-960D-3CC08F909719Q35556196-6D8F6FCA-B9A7-4BC0-8DD1-06B4286A3713Q36062739-7D8BD3A9-7C69-4642-9928-287428CB4111Q36326096-C928FB3E-988B-4266-AF80-A8CC97EE82B7Q36332721-D6DE0368-1CDE-4663-A39C-5609742BBDA8Q36559181-C48FE844-383B-42C4-98F3-8DF5DF8C9A62Q37373400-9831527E-6219-4D80-A58D-82724CAA212FQ37415795-46461A34-AAB0-4C74-B1AF-B6AE72695606Q37441427-D129362A-016F-424A-8E3B-E4EE350E31D2Q37461417-DFC02344-B471-465F-863C-4B2557ACDB69Q37671608-2E0DF9A0-F603-4F60-9987-EA5F0018543CQ37671696-4C038F61-CD17-4C03-826A-365554A2FC50Q38263375-A20744D5-8E9D-48D5-A0BB-6469A741E732Q38474104-98A631F5-4BFB-4B26-B2A5-27717EC1DAF6Q38577301-7422AD8D-CAD0-48E0-A3A4-5DFCE2DFFD40Q38634816-B3B3B680-BC99-49AE-90A5-086B817E6083Q38649685-AC7926CB-C1E4-46BF-89DA-8A122869F6A7Q38668143-EBBEA6E4-EEF0-4487-BB14-73FD5F7BC1F8Q38765381-E6D151CA-E246-4469-BA37-9C9387C16906Q38819016-57023EA9-C6FD-4F4D-B3A0-BA798CC37D82Q38845396-5F5C5151-15BE-4071-87B5-573FCEF44D50Q38859664-9C0E6D9B-22B3-436E-AD37-49CA7D50A4EFQ38870480-EA55F4F2-1F27-4C53-A869-00071CEB3284Q38911819-23B6DAF7-33D1-4D81-81A0-ADAE09088BA8Q39013697-1095F192-DD33-44B1-B1B1-BA09DF1F8E35Q39046374-2C4B3AB0-5C7F-4B45-A2B1-72B6F26E33C2Q39874458-B8ACAA06-51A0-4DB6-AACD-B0DECDFB9453Q40068468-FD1D25A8-4B1F-495E-BD32-E2C2FC8716C6Q40210488-5FDD23B8-3914-4DF4-A18D-3ABB8DEC99B0Q40691097-8B4B1A1A-7BF9-44F4-8C9E-95EBE9FDAFD1
P2860
Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.
@en
type
label
Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.
@en
prefLabel
Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.
@en
P1476
Long-term adherence to antimuscarinic therapy in everyday practice: a systematic review.
@en
P2093
J L H Ruud Bosch
Paul W Veenboer
P304
P356
10.1016/J.JURO.2013.10.046
P407
P577
2013-10-16T00:00:00Z